Monday, October 15, 2018 4:27:34 PM
Hi Jason,
I don't follow the company closely but I have my doubts. Its quite dubious to NOT take questions when there naturally are some.
Its worth noting they have a shelf that just came into effect... It sure smells of an offering to me but I'm certainly no expert.
Here is what I tweeted earlier
https://twitter.com/MauriceOnTW/status/1051881632360218625
Webcast link: https://edge.media-server.com/m6/p/5d7wxq73
8-k (slides) link: https://www.sec.gov/Archives/edgar/data/1711279/000119312518298897/0001193125-18-298897-index.htm
I don't follow the company closely but I have my doubts. Its quite dubious to NOT take questions when there naturally are some.
Its worth noting they have a shelf that just came into effect... It sure smells of an offering to me but I'm certainly no expert.
Here is what I tweeted earlier
https://twitter.com/MauriceOnTW/status/1051881632360218625
@MauriceOnTW
$KRYS up 30% on questionable N=2 data. They didn't take questions though 
.
Main one that comes to mind is patients were older (for EB) and one (placebo) wound healed on its own (though took longer) so how severe were the treated wounds?
$ABEO $FSCS
Webcast link: https://edge.media-server.com/m6/p/5d7wxq73
8-k (slides) link: https://www.sec.gov/Archives/edgar/data/1711279/000119312518298897/0001193125-18-298897-index.htm
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
